Incyte Corp

10 jun 2026, 21:02 UTC

Incyte shares rise in after-market trading on Guggenheim target increase.

9 jun 2026, 20:02 UTC

Incyte Corp gains as HC Wainwright raises price target to $140 and the company announces a $1.25 billion acquisition of Vega Therapeutics.

8 jun 2026, 19:42 UTC

Incyte Corp shares are lower after announcing a $1.25 billion acquisition of Vega Therapeutics, which will impact upcoming financial results significantly.

5 jun 2026, 22:51 UTC

Incyte Corp shares are higher in after-market trading, reflecting positive market sentiment following stronger-than-expected U.S. job growth data.

4 jun 2026, 20:01 UTC

Incyte shares rise as results from the Phase 2 PROGRESS study will be presented at ENDO 2026, supporting the FDA's Priority Review of its application.

3 jun 2026, 20:02 UTC

Incyte Corp shares are higher today, breaking a recent trend. The ADP Employment Report showed stronger-than-expected job growth, influencing broader market sentiment.

2 jun 2026, 23:06 UTC

Incyte Corp. shares are trading roughly flat in after-market hours, following a session that saw a peak gain earlier.

1 jun 2026, 19:36 UTC

Incyte Corp's stock is lower after the Phase 3 frontMIND trial results raised safety concerns despite showing efficacy in treating high-risk lymphoma patients.

29 may 2026, 23:46 UTC

Incyte Corp shares are lower in after-market hours, reflecting a slight decline since Friday's close without any specific news to explain the movement.

28 may 2026, 20:06 UTC

Incyte Corp shares are higher today, recovering from earlier losses amid modest overall market performance. No specific company news was identified to explain the movement.

27 may 2026, 23:06 UTC

Incyte Corp. shares remain roughly flat in after-market trading, with no specific news identified and movement within a narrow range since Wednesday's close.

26 may 2026, 20:06 UTC

Incyte Corp. shares are lower today, reflecting a decline since Friday's close amid broader market focus on upcoming economic data releases.

21 may 2026, 19:26 UTC

HC Wainwright & Co. reiterated a Buy rating on Incyte Corp with a $135 price target, contributing to the stock's upward movement since Wednesday.

20 may 2026, 23:56 UTC

Incyte Corp shares are lower in after-market trading, amid tightening global financial conditions and rising policy rates. The broader market has shown recent strength.

19 may 2026, 19:36 UTC

Incyte Corp partners with Edison Scientific to use AI in drug discovery. Shares are trading higher, reflecting broader gains in the Biotechnology sector.

18 may 2026, 19:17 UTC

Incyte Corp shares decline amid rising Treasury yields and broader market pressures. The stock has finished lower for five consecutive sessions.

15 may 2026, 23:02 UTC

Incyte Corp shares are higher in after-market trading, reversing four consecutive daily declines. No specific news was identified to explain the price movement.

14 may 2026, 20:06 UTC

Incyte Corp shares are lower today amid a downturn in the Biotechnology sub-sector and a broader market decline over three consecutive sessions.

13 may 2026, 20:13 UTC

Incyte Corp shares are lower in after-market trading, continuing a downward trend since Wednesday. No specific company news was identified to explain the movement.

12 may 2026, 19:11 UTC

Incyte Corp shares decline despite positive news on EHA Congress. Director Baker Bros. Advisors exercised options for 30,000 shares at $84.53.

11 may 2026, 22:51 UTC

Incyte Corp shares have declined in after-hours trading. This drop coincides with cautious market sentiment ahead of inflation reports, despite trading above its 20-day moving average.

8 may 2026, 19:16 UTC

Incyte Corp shares rise as final data from TRuE-AD4 study released. The study evaluated Opzelura® cream's efficacy for moderate atopic dermatitis.

7 may 2026, 20:15 UTC

Incyte Corp holds steady in after-hours trading. The stock remains above its 20-day moving average, indicating strong performance.

6 may 2026, 19:36 UTC

Incyte Corp trades higher, reflecting broader market optimism. Strong U.S. job growth supports bullish sentiment, aligning with recent positive trends in equity markets.

5 may 2026, 23:01 UTC

Incyte Corp's shares declined in after-hours trading. No specific company news has been identified to explain this downturn.

4 may 2026, 19:46 UTC

Incyte gains FDA approval for Jakafi XR, enhancing treatment options. Shares remain stable amid broader market conditions despite this positive news.

1 may 2026, 23:06 UTC

Incyte Corp gains FDA approval for Jakafi XR today. The new formulation enhances treatment options for myelofibrosis and GVHD, boosting shares in after-hours trading.

30 abr 2026, 19:51 UTC

Incyte Corp trades lower, falling below its 20-day moving average. This decline contrasts with three consecutive sessions of gains, with no specific news identified.